Topic - Valeant Pharmaceuticals International Inc.

Related Stories

FILE - In this June 14, 2016, file photo, Valeant Pharmaceuticals chairman and CEO Joe Papa speaks to reporters after the company's annual meeting in Laval, Quebec. Valeant Pharmaceuticals now wants to be called Bausch Health Companies, as the Canadian drugmaker continues to distance itself from notoriety gained a few years ago by dramatically hiking the prices of treatments it acquired. Papa said in a statement that the new identity was “a major step forward” in his company’s transformation. (Ryan Remiorz/The Canadian Press via AP, File)

Valeant, a new business model and now, a new name

Associated Press

Activist investor Ackman’s hedge fund sells Valeant stake

By LINDA A. JOHNSON - Associated Press

Valeant sells $2B in assets to begin paying down debt

Associated Press

Valeant Pharma picks Joseph Papa, Perrigo leader, to become next CEO

Associated Press

Business Highlights

By The Associated Press - Associated Press

FILE - This Feb. 6, 2012, file photo, shows William Ackman, of Pershing Square Capital Management, in Toronto. It was announced Monday, May 12, 2014, that Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited bid worth nearly $46 billion undervalues the company and carries significant risk. Shortly after Canada’s Valeant and activist investor Ackman made their offer public last month, Allergan announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive. (AP Photo/The Canadian Press, Pawel Dwulit, File)

Allergan board turns down Valeant takeover offer

Associated Press

Botox maker Allergan draws bid from Valeant

By KEN SWEET and MATTHEW PERRONE - Associated Press

Valeant to bid for Botox maker Allergan

By KEN SWEET and MATTHEW PERRONE - Associated Press

Teva buying Cephalon for $6.8 billion

By DAMIAN TROISE - Associated Press

Israeli generic drug firm buys Cephalon

By Damian Troise - Associated Press